Document Detail


BCG in management of superficial bladder cancer.
MedLine Citation:
PMID:  3318088     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Superficial bladder cancer and particularly carcinoma in situ has the potential for invasiveness for which the treatment is cystectomy with a resultant disappointing 50 per cent five-year survival and urinary diversion with a certain diminished quality of life. BCG therapy is a new method of treating aggressive superficial bladder cancer with better response rates than conventional chemotherapy. It may be immunologically mediated and, if so, may be the first major success of a therapeutic modality that offers less morbidity than the currently standard options of surgery, radiotherapy, or chemotherapy.
Authors:
P Guinan; R Crispen; M Rubenstein
Related Documents :
21729158 - Cancer screening practices among amish and non-amish adults living in ohio appalachia.
10614978 - Bladder cancer in women.
11439368 - Microarrays of bladder cancer tissue are highly representative of proliferation index a...
15168998 - Bladder preserving approach for muscle invasive bladder cancer--role of mycobacterium w.
17228018 - Cisplatin-induced long-term hearing impairment is associated with specific glutathione ...
12924748 - The clinical opiate withdrawal scale (cows).
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Urology     Volume:  30     ISSN:  0090-4295     ISO Abbreviation:  Urology     Publication Date:  1987 Dec 
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0366151     Medline TA:  Urology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  515-9     Citation Subset:  IM    
Affiliation:
Institute for Tuberculosis Research, Cook County Hospital, Chicago, Illinois.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intravesical
Algorithms
BCG Vaccine / therapeutic use*
Carcinoma in Situ / therapy*
Carcinoma, Transitional Cell / therapy*
Clinical Trials as Topic
Humans
Urinary Bladder Neoplasms / therapy*
Chemical
Reg. No./Substance:
0/BCG Vaccine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current status of vaccine development in sexually transmissible diseases
Next Document:  Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: multicent...